National Institute for Health and Clinical Excellence (NICE)
NICE recommends potentially life-changing treatment for people with short bowel syndrome
A potentially life-changing treatment has been recommended for people with short bowel syndrome who are aged 1 year and above after NICE published final draft guidance today (01 June 2022)
Teduglutide (also known as Revestive and made by Takeda) is available for people who are in a stable condition following surgery to remove an abnormal bowel.
In adults, this surgery may be needed for a range of conditions, including Crohn’s disease. In premature babies and children, it is often because of surgery for necrotising enterocolitis or other conditions. Some children can be born with a short bowel.
Teduglutide helps to improve the absorption of nutrients and fluid from the remaining intestine. The company estimates there are around 70 people eligible for the treatment.
Short bowel syndrome is a chronic and potentially life-threatening condition in which the body is unable to absorb enough nutrients from food. The condition occurs when people do not have enough small intestine, which is the part of the body where most nutrients are absorbed during digestion.
Short bowel syndrome is currently treated by giving people nutrients and fluids intravenously through a drip, also known as parenteral support, alongside best supportive care. Best supportive care can include treatments which control bowel movements, fluid restriction and diet changes.
Clinical trial evidence shows that teduglutide reduces the number of days a week people with short bowel syndrome need parenteral support compared with placebo.
Helen Knight, interim director of medicines evaluation in the NICE Centre for Health Technology Evaluation, said: “Current treatments for short bowel syndrome are lifesaving, but they can be very complex, time consuming and can lead to severe complications. People with short bowel syndrome currently need parenteral support which can be required for as much as 14 hours a day, 7 days a week.
“NICE’s independent appraisal committee heard that people with short bowel syndrome often have very limited quality of life and there is a heavy burden placed on them and their carers by having to administer treatment at home. Clinical evidence showed teduglutide can help give people with short bowel syndrome greater normality by reducing the number of days per week people would require parenteral support. I am therefore delighted we can recommend teduglutide for some people with this condition.”
Caroyln Wheatley, Chair of PINNT (Support and advocacy for people on home artificial nutrition) said: “Today represents a landmark day for people with short bowel syndrome. Living with short bowel syndrome is incredibly difficult for people due to the current treatment options that are available to us. While lifesaving, home parenteral nutrition is a complex treatment that comes with risks. It can severely impact quality of life. This treatment is a game-changer because it will reduce the burden on people with short bowel syndrome, their families and their carers.”
The recommended daily dose of teduglutide is 0.05 mg per kg body weight. The dose will be given in millilitres (ml) of solution.
Teduglutide is injected under the skin (subcutaneously) once daily. The injection can be self-administered or given by another person such as your doctor or carer.
Latest News from
National Institute for Health and Clinical Excellence (NICE)
New UK valuation study for EQ-5D quality of life questionnaire to start this year18/08/2022 11:15:00
Blog posted by: Sophie Cooper, scientific adviser in NICE's Science, Policy and Research programme, 16 August 2022.
NICE publishes first draft guidance from its Early Value Assessment pilot project recommending smartphone-linked ECG device15/08/2022 11:15:00
It is the first recommendation to be issued by NICE’s diagnostics advisory committee via its Early Value Assessment pilot project.
NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 201814/07/2022 13:05:00
An agreement with the companies on the price of 2 breast cancer treatments, Piqray and Trodelvy, has paved the way for NICE to be able to make them available immediately to around 3,450 people on the NHS and maintaining NICE’s 100% approval rate of breast cancer drugs since 2018
NICE recommends step-change targeted treatment for people with early breast cancer17/06/2022 16:20:00
Around 4,000 people are set to benefit from a step-change in treatment for early breast cancer following today’s (17 June 2022) provisional approval by NICE of abemaciclib in combination with hormone therapy as an option after surgery
New treatment to increase the chances of a successful kidney transplant recommended by NICE17/06/2022 12:10:00
A new treatment that increases the chance of a successful kidney transplant has been recommended by NICE in final draft guidance
A ‘safe space’ for addressing complex health technology assessment challenges16/06/2022 11:15:00
Nick Crabb discusses how we’re developing a collaborative space for research and development, to help us create new methods and processes for health technology assessment.
Hundreds of thousands set to benefit as NICE final draft guidance recommends new treatment to prevent heart attacks and strokes in people with raised blood fats13/06/2022 09:15:00
NICE recently (10 June 2022) published final draft guidance which recommends icosapent ethyl for reducing the risk of cardiovascular events such as heart attacks and strokes in adults who have raised levels of a type of blood fat called triglycerides.
NICE sets out further details on menopause guideline update27/05/2022 12:15:00
NICE has outlined what aspects of menopause care will be updated in upcoming guidance, including areas where more research is needed
New injectable immunotherapy treatment for rare form of triple negative breast cancer recommended by NICE26/05/2022 16:20:00
An estimated 100 people per year with triple negative breast cancer that has spread to other parts of the body may soon benefit from pembrolizumab in combination with chemotherapy (paclitaxel or nab-paclitaxel) following the final draft recommendation from NICE.